Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxygen Biotherapeutics secures first license for glucose biosensor

This article was originally published in Clinica

Executive Summary

Costa Mesa, California-based Oxygen Biotherapeutics has signed its first licensing deal for its glucose biosensor technology with Glucometrics. The licence allows Glucometrics to use the Oxycyte perfluorocarbon therapeutic oxygen carrier technology for applications involving the measurement and monitoring of glucose levels in diabetic patients. In exchange, Oxygen Biotherapeutics will receive Glucometrics stock and royalties based on the worldwide net revenues from the products resulting from the deal. Further financial details were not disclosed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042637

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel